Low levels of high density lipoprotein cholesterol in patients with active sarcoidosis

Atherosclerosis

Volumn 136, Issue 1, 1998, Pages 133-137

  Salazar, Albert ^a   Maña, Juan ^a   Pinto, Xavier ^a   Argimon, Josep M ^c   Castiñeiras, Maria J ^b   Fiol, Concepcion ^b   Pujol, Ramon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c Epidemiology Unit   (Spain)

Author keywords

Activity; Cholesterol; Dyslipoproteinemia; Sarcoidosis

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DISEASE ACTIVITY; DYSLIPIDEMIA; DYSLIPOPROTEINEMIA; FEMALE; GRANULOMATOSIS; HUMAN; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SARCOIDOSIS;

APOLIPOPROTEIN A-I; APOLIPOPROTEINS B; CHOLESTEROL; CHOLESTEROL, HDL; CHOLESTEROL, LDL; HUMANS; LIPOPROTEINS; LIPOPROTEINS, HDL; LIPOPROTEINS, HDL2; LIPOPROTEINS, HDL3; SARCOIDOSIS; TRIGLYCERIDES;

EID: 0344936568     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(97)00198-6     Document Type: Article

References (41)

1. Thomas P.D., Hunninghake G.W. Current concepts of the pathogenesis of sarcoidosis. Am Rev Respir Dis. 135:1987;747-760.
2. Almenoff J.A., Teirstein A.S. Clinical significance of serum thermolysin-like metalloendopeptidase and its relationship to serum angiotensin converting enzyme in sarcoidosis. Am J Med. 82:1987;33-37.
3. Slater H.R., Packard C.J., Shepherd J. Receptor-independent catabolism of low density lipoprotein. Involvement of the reticuloendothelial system. J Biol Chem. 257:1982;307-310.
4. Gilbert H.S., Ginsberg H., Fagerstrom R., Brown W.V. Characterization of hypocholesterolemia in myeloproliferative disease. Relation to disease manifestations and activity. Am J Med. 71:1981;595-602.
5. Gilbert H.S., Ginsberg H. Hypocholesterolemia as a manifestation of disease activity in chronic myelogenous leukemia. Cancer. 51:1983;1428-1433.
6. Ginsberg H.N., Gilbert H.S., Gibson J.C., Le N.A., Brown W.V. Increased low density lipoprotein catabolism in myeloproliferative disorders. Ann Intern Med. 71:1982;595-602.
7. Ginsberg H.N., Le N.A., Gilbert H.S. Altered high density lipoprotein metabolism in patients with myeloproliferative disorders and hypocholesterolemia. Metabolism. 35:1986;878-882.
8. Ginsberg H.N., Goldberg I., Wang-Iverson P., Gitler E., Le N.A., Gilbert H.S., Brown W.V. Increased catabolism of native and cyclohexanedione modified low density lipoprotein in subjects with myeloproliferative diseases. Arteriosclerosis. 3:1983;233-241.
9. Ginsberg H., Grabowski G.A., Gibson J.C., Fagerstrom R., Goldblatt I, Gilbert H.S., Desnick R.J. Reduced plasma concentrations of total, low density lipoprotein and high density lipoprotein cholesterol in patients with Gaucher type I disease. Clin Genet. 26:1984;109-116.
10. Le N.A., Gibson J.C., Rubenstein A., Grabowski G.A., Ginsberg H.N. Abnormalities in lipoprotein metabolism in Gaucher type I disease. Metabolism. 37:1988;240-245.
11. Svenson K.L.G., Lithell H., Hallgren R., Selinus I., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. I. Relativity to inflammatory activity. Arch Intern Med. 147:1987;1912-1916.
12. Svenson K.L.G., Lithell H., Hallgren R., Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritides. II. Effects of anti-inflammatory and disease modifying drug treatment. Arch Intern Med. 147:1987;1917-1920.
13. Kindman L.A., Gilbert H.S., Almenoff J.S., Ginsberg H., Fagerstrom R., Teirstein A.S. High-density lipoprotein cholesterol is reduced in patients with sarcoidosis. Am J Med. 86:1989;376-378.
14. Mañá J., Badrinas F., Morera J., Fité E., Manresa F., Fernández-Nogués F. Sarcoidosis in Spain. Sarcoidosis. 9:1992;118-122.
15. James DG, Jones Williams W. Criteria of activity. In: Smith LH, editor. Sarcoidosis and Other Granulomatous Disorders. Philadelphia: Saunders, 1985:192-198.
16. Mañá J., Salazar A., Manresa F. Clinical factors predicting persistence of activity in sarcoidosis: A multivariate analysis of 193 cases. Respiration. 61:1994;219-225.
17. Mañá J., Salazar A., Pujol R., Manresa F. Are the pulmonary function tests and the markers of activity helpful to establish the prognosis of sarcoidosis? Respiration. 63:1996;298-303.
18. 2+ precipitation procedure for quantitative determination of high density lipoprotein cholesterol. Clin Chem. 28:1982;1379-1388.
19. 2 precipitation technique in human serum. Clin Chim Acta. 158:1986;33-41.
20. Ilowite N.T., Samuel P., Ginzler E., Jacobson M.S. Dyslipoproteinemia in pediatric systemic lupus erythematosus. Arthritis Rheum. 31:1988;859-863.
21. Lahita R.G., Rivkin E., Cavanagh I., Romano P. Low levels of total cholesterol, high-density lipoprotein, and apolipoprotein A-1 in association with anticardiolipin antibodies in patients with systemic lupus erythematosus. Arthritis Rheum. 36:1993;1566-1574.
22. Borba E.F., Santos R.D., Bonfa E., Vinagre C.G., Pileggi F.J., Cossermelli W., Maranhao R.C. Lipoprotein(a) levels in systemic lupus erythematosus. J Rheumatol. 21:1994;220-223.
23. Leong K.H., Koh E.T., Feng P.H., Boey M.L. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol. 21:1994;1264-1267.
24. Ettinger W.H., Hazzard W.R. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab. 67:1988;425-428.
25. Ettinger W.H., Goldberg A.P., Applebaum-Bowden D., Hazzard W.R. Dyslipoproteinemia in systemic lupus erythematosus. Effect of corticosteroids. Am J Med. 83:1987;503-508.
26. Ettinger W.H., Klinefelter H.K., Kwiterovitch P.O. Effect of short term, low dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 63:1987;167-172.
27. Rössner S., Löfmark C. Dyslipoproteinemia in patients with active chronic polyarthritis: A study on serum lipoproteins and triglyceride clearance. Atherosclerosis. 28:1977;41-46.
28. Lorber M., Aviram M., Linn S., Scharf Y., Brook J.G. Hypocholesterolemia and abnormal high-density lipoprotein in rheumatoid arthritis. Br J Rheumatol. 24:1985;250-255.
29. Rohatgi P.K., Ryan J.W., Lindeman P. Value of serial measurement of serum angiotensin converting enzyme in the management of sarcoidosis. Am J Med. 70:1981;44-50.
30. Hardardottir I., Moser A.H., Memon R., Grunfeld C., Feingold K.R. Effects of TNF, IL-1, and the combination of both cytokines on cholesterol metabolism in Syrian hamsters. Lymphokine Cytokine Res. 13:1994;161-166.
31. Keicho N., Kitamura K., Takaku F., Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 98:1990;1125-1129.
32. Prior C., Haslam P.L. Increased levels of serum interferon-gamma in pulmonary sarcoidosis and relationship with response to corticosteroid therapy. Am Rev Respir Dis. 143:1991;53-60.
33. Ina Y., Takada K., Sato T., Yamamoto M., Noda M., Morishita M. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible origin. Chest. 102:1992;1128-1133.
34. Steffen M., Petersen J., Oldigs M., Karmeier A., Magnussen H., Thiele H.G., Raedler A. Increased secretion of tumor necrosis factor-alpha, interleukin-1-beta, and interleukin-6 by alveolar macrophages from patients with sarcoidosis. J Allergy Clin Immunol. 91:1993;939-949.
35. Beutler B.A., Cerami A. Recombinant interleukin 1 suppresses lipoprotein lipase activity in 3T3-L1 cells. J Immunol. 135:1985;3969-3971.
36. Duff G.W. Cytokines and acute phase proteins in rheumatoid arthritis. Scand J Rheumatol Suppl. 100:1994;9-19.
37. Liang J.S., Sipe J.D. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulate cholesterol flux. J Lipid Res. 36:1995;37-46.
38. Marhaug G., Dowton S.B. Serum amyloid A: An acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin Rheumatol. 8:1994;553-573.
39. Kumon Y., Suehiro T., Ikeda Y., Yoshida K., Hashimoto K., Ohno F. Influence of serum amyloid A protein on high-density lipoprotein in chronic inflammatory disease. Clin Biochem. 26:1993;505-511.
40. Steinmetz A., Hocke G., Saïle R., Puchois P., Fruchart J.C. Influence of serum amyloid A on cholesterol esterification in human plasma. Biochim Biophys Acta. 1006:1989;173-178.
41. Rubinstein I., De Beer F.C., Pras M., Knecht A., Baum G.L. Serum amyloid A protein concentrations in sarcoidosis. Isr J Med Sci. 25:1989;461-462.